Skip to main content

Advertisement

Table 2 Univariate and multivariate analyses of variables associated with progression-free survival of patients with newly diagnosed metastatic colorectal cancer

From: Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy

Characteristic Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Gender 0.931
 Male 1 (reference) 0.870 1 (reference)  
 Female 0.984 (0.815–1.189)   0.992 (0.819–1.200)  
Age (years) 0.837
 <65 1 (reference) 0.931 1 (reference)  
 ≥65 0.991 (0.714–1.207)   0.837 (0.668–1.408)  
ECOG performance status <0.001
 <2 1 (reference) 0.009 1 (reference)  
 ≥2 1.300 (1.066–1.585)   1.515 (1.206–1.907)  
Site of primary tumor 0.560
 Colon 1 (reference) 0.542 1 (reference)  
 Rectum 1.060 (0.878–1.280)   1.058 (0.876–1.278)  
No. of metastatic sites 0.049
 ≤2 1 (reference) 0.001 1 (reference)  
 >2 1.388 (1.148–1.680)   1.229 (1.001–1.509)  
Tumor differentiation 0.005
 Well or moderate 1 (reference) <0.001 1 (reference)  
 Poor 1.617 (1.334–1.961)   1.354 (1.095–1.675)  
Pre-chemotherapy ALC (× 109/L) 0.059
 <2.70 1 (reference) 0.072 1 (reference)  
 ≥2.70 0.841 (0.697–1.015)   0.792 (0.621–1.009)  
Pre-chemotherapy AMC (× 109/L) 0.001
 <0.55 1 (reference) 0.001 1 (reference)  
 ≥0.55 1.409 (1.159–1.713)   1.513 (1.172–1.954)  
Pre-chemotherapy LMR 0.005
 <3.11 1 (reference) <0.001 1 (reference)  
 ≥3.11 0.552 (0.454–0.671)   0.710 (0.558–0.903)  
  1. HR hazard ratio, CI confidential interval. Other abbreviations as in Table 1